✦ LIBER ✦

Incidence of Acute Rejection in African-American Liver Transplant Recipients

✍ Scribed by M Maggard; J Goss; S Ramdev; K Swenson; R.W Busuttil

Book ID: 117236177
Publisher: Elsevier Science
Year: 1998
Tongue: English
Weight: 144 KB
Volume: 30
Category: Article
ISSN: 0041-1345
DOI: 10.1016/s0041-1345(98)00330-3

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Incidence of non-cellular acute rejectio

Incidence of non-cellular acute rejection in heart transplant recipients

✍ J.P. Naour; K. Malinowska; B.A. Pisani; J.C. Mendez; R.C. Lichtenberg; J.A. Robi 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Incidence and severity of acute allograf

Incidence and severity of acute allograft rejection in liver transplant recipients treated with alfa interferon

✍ Jain, Ashokkumar ;Demetris, Anthony J. ;Manez, Rafael ;Tsamanadas, Athanassisos 📂 Article 📅 1998 🏛 Wiley (John Wiley & Sons) 🌐 English ⚖ 195 KB 👁 1 views

Interferon alfa-2b (IFN-alpha) therapy has been shown to be effective in the treatment of viral hepatitis B (HBV) or viral hepatitis C (HCV) in patients who did not undergo transplantation. However, in allograft recipients, treatment with IFN-alpha often leads to allograft rejection. The aim of the

247: Decreased Incidence of Acute Cardia

247: Decreased Incidence of Acute Cardiac Allograft Rejection in Combined Heart and Liver Transplant Recipients

✍ J. Jahanyar; M. Loebe; C. Orrego; J.A. Goss; B. Bruckner; R. Celis; M.M. Koerner 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 127 KB

Outcomes of acute rejection after interf

Outcomes of acute rejection after interferon therapy in liver transplant recipients

✍ Sammy Saab; Denise Kalmaz; Nupoor A. Gajjar; Jonathan Hiatt; Francisco Durazo; S 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 229 KB 👁 1 views

Interferon alfa has been increasingly used against recurrent hepatitis C (HCV) disease in post-liver transplant (LT) recipients. A serious potential adverse effect is acute rejection. We reviewed our experience using interferonbased therapy (interferon or pegylated interferon with or without ribavir

Ursodeoxycholic acid for prevention of a

Ursodeoxycholic acid for prevention of acute rejection in liver transplant recipients

✍ Persson, Hans; Friman, Styrbjörn; Scherstén, Tore; Svanvik, Joar; Karlberg, Ingv 📂 Article 📅 1990 🏛 The Lancet 🌐 English ⚖ 337 KB

Acute rejection in HCV-infected liver tr

Acute rejection in HCV-infected liver transplant recipients: The great conundrum

✍ James R. Burton Jr.; Hugo R. Rosen 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB 👁 1 views

1. In hepatitis C virus (HCV)-infected patients, treatment of acute rejection is associated with worse outcomes (increased risk of allograft cirrhosis and mortality). 2. Whether patients with HCV are at higher risk for rejection remains controversial. 3. The mechanisms mediating acute rejection and